Market Overview

UPDATE: Jefferies Reduces PT to $52 on CVS Caremark on Competitive Pressures

Related CVS
Top 4 Stocks In The Drug Stores Industry With The Highest Dividend Yield
5 Ways Walmart's Care Clinics Could Disrupt Medical Care
Rite Aid Halves 1Q Profit as Costs Grow (Fox Business)

Jefferies reiterated its Buy rating on CVS Caremark (NYSE: CVS) but lowered its price target from $52 to $50.

Jefferies noted, "While we recognize that the ESRX/WAG deal has taken some of the air out of the CVS story, the company's advantaged business model, significant cash flow, and solid management, suggest CVS is undervalued. Indeed, even though we have slightly lowered our FY13 forecast to account for some of the ESRX business returning to WAG, given the strength in the business, we would not be surprised if CVS exceeds our forecasts for FY12 & 13."

CVS Caremark closed at $44.12 on Tuesday.

Posted-In: JefferiesAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (CVS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters